Not that Schering-Plough Corp didn't have other marketed...

Not that Schering-Plough Corp didn't have other marketed drugs at acquisition, but;

"Merck gained Keytruda in the 2009 acquisition of Schering-Plough Corp. for $41 billion, and the drug accounted for 37% of the company's worldwide sales in the second quarter of 2021"

There is lots to factor in, and yea forget inflation over the years.

But let's just say CF33 on its own or Oncarlytics with Azer-cel is able to compete with keytruda and is safe.

"At evaluation, 67% (185 / 227) of patients were alive in the Keytruda every 3 weeks group, compared to 60% (166 / 278) of patients in the Yervoy group. At 4.1 months, the cancer in half of the patients in the Keytruda group had not spread, grown larger, or worsened."

Well, keytruda's patent happens to end in 2028. Don't get me wrong, there is a lot of water to go under the bridge, but current trial data is fairly compelling against a blockbuster drug. We just need a bit more time to get some Oncarlytics trial data and see if BP has an appetite.

But yea, I'm content to wait it out.